Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

697
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
697
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

935
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
935
Survival Tree01:19

Survival Tree

464
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a...
464
Censoring Survival Data01:09

Censoring Survival Data

630
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
630
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

321
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
321
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

902
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
902

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Neighborhood Deprivation Linked to Medication Level Variability in Liver Transplant Recipients.

Clinical transplantation·2025
Same author

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.

Cancer·2025
Same author

Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].

Breast (Edinburgh, Scotland)·2025
Same author

PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.

JCO precision oncology·2025
Same author

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial.

Breast (Edinburgh, Scotland)·2025
Same journal

A statistical evaluation of decision-making methods and the efficiency of Bayesian multi-arm multi-stage trials.

Clinical trials (London, England)·2026
Same journal

Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.

Clinical trials (London, England)·2026
Same journal

Phase I design for partially ordered groups with late-onset toxicity.

Clinical trials (London, England)·2026
Same journal

Trial informed consent forms, the Declaration of Helsinki and the SPIRIT 2025 statement.

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Morning panel discussion).

Clinical trials (London, England)·2026
Same journal

17th Annual University of Pennsylvania Conference on statistical issues in clinical trials - Covariate adjustment in randomized clinical trials: New methods and applications (Afternoon panel discussion).

Clinical trials (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 22, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K

Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.

Wai-Ki Yip1, Marco Bonetti2, Bernard F Cole3

  • 1Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA wyip@jimmy.harvard.edu.

Clinical Trials (London, England)
|April 21, 2016
PubMed
Summary
This summary is machine-generated.

This study extends the Subpopulation Treatment Effect Pattern Plot (STEPP) method to analyze diverse clinical trial outcomes. The enhanced STEPP approach enables personalized medicine by assessing treatment effectiveness across patient subgroups, improving tailored therapy development.

Keywords:
Generalized linear modelSubpopulation Treatment Effect Pattern Plot (STEPP)randomized clinical trialsubgroup analysis

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

846

Related Experiment Videos

Last Updated: Mar 22, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

846

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Personalized Medicine

Background:

  • Randomized clinical trials (RCTs) provide effective treatments but offer one-size-fits-all recommendations.
  • Personalized medicine investigates how patient characteristics modify treatment effects (heterogeneity of treatment effects).
  • Understanding treatment-covariate interactions enables tailored therapies and improved patient outcomes.

Purpose of the Study:

  • To extend the Subpopulation Treatment Effect Pattern Plot (STEPP) approach for analyzing heterogeneity of treatment effects.
  • To adapt STEPP for continuous, binary, and count outcomes using generalized linear models.
  • To assess statistical significance of treatment heterogeneity using permutation tests.

Main Methods:

  • Generalized linear models applied to well-defined patient subgroups.
  • Estimation of treatment effects within subpopulations based on a covariate.
  • Permutation tests to assess statistical significance of observed heterogeneity.

Main Results:

  • Simulation studies confirmed appropriate Type I error rates without heterogeneity.
  • Power studies demonstrated the method's ability to detect treatment heterogeneity.
  • Application to the Aspirin/Folate Polyp Prevention Study illustrated the method's utility.

Conclusions:

  • The extended STEPP method accommodates a wider range of clinical trial endpoints.
  • New software, an extension of the R package 'stepp', is available on CRAN.
  • This advancement facilitates the application of STEPP to diverse clinical trial data for personalized treatment strategies.